Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication

The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.

More from Archive

More from Pink Sheet